Streetbeat News

Stock Prices

PTLO

Portillo's shares are trading lower due to worse-than-expected Q1 sales results.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 6:53 pm

MSFT

NVDA

Stanley Druckenmiller, a billionaire investor and former employee of George Soros, has reduced his investment in Nvidia Corp (NVDA) after the stock's significant surge, attributing the decision to the rapid acceleration of the AI market. Druckenmiller, who has been investing in AI through stocks like Nvidia and Microsoft Corp (MSFT), cited Nvidia's stock price increase from $150 to over $900 in just over a year as a reason for the reduction. Despite this, he remains bullish on AI's long-term prospects, comparing its potential impact to that of the internet.

Portfolio Pulse from Adam Eckert

May 07, 2024 | 6:49 pm

IMAB

I-MAB's (NYSE:IMAB) short interest has significantly increased by 113.98% since the last report, with 1.30 million shares sold short, representing 3.98% of its float. This indicates a bearish market sentiment towards IMAB, despite the short interest being lower than its peer group average of 9.63%. The current short interest suggests it would take approximately 5.85 days for traders to cover their positions, based on recent trading volumes.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 6:45 pm

MYSZ

My Size, Inc. (NYSE:MYSZ) has seen a significant increase in short interest, with a 2063.64% rise since the last report, representing 7.14% of its float. This indicates a bearish market sentiment towards MYSZ, although it's not a definitive predictor of stock price movement. The short interest in MYSZ is higher than its peer group average of 4.84%, suggesting more bearish sentiment compared to its peers.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 6:45 pm

AMGN

Amgen's (NYSE:AMGN) short interest has decreased by 3.57%, with 10.11 million shares sold short, representing 1.89% of its float. This decline in short interest could indicate a more bullish sentiment towards AMGN among traders. Compared to its peers, AMGN has a lower short interest percentage of float, with the average for its peer group being 5.96%.

Portfolio Pulse from Benzinga Insights

May 07, 2024 | 6:45 pm

NVO

Novo Nordisk has requested additional time to respond to Senator Bernie Sanders regarding inquiries about the pricing of Ozempic, aiming to extend their deadline past May 8.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 6:37 pm

ONON

Telsey Advisory Group analyst Cristina Fernández maintained an Outperform rating on On Holding AG (NYSE:ONON) with a price forecast of $37, ahead of its Q1 results on May 14. Fernández anticipates strong sales growth driven by new product introductions across various categories and significant margin expansion. The analyst projects an 18.5% year-over-year sales growth to CHF 498 million and an EBITDA of CHF 76 million, indicating an EBITDA margin expansion to 15.3%. The company's focus on direct-to-consumer sales and expansion into new markets and categories is highlighted as key growth drivers.

Portfolio Pulse from Nabaparna Bhattacharya

May 07, 2024 | 6:35 pm

BYON

GSUN

NUVO

RGF

Beyond, Inc. (NYSE:BYON) shares plummeted over 20% due to disappointing quarterly results, missing both earnings and revenue estimates. Other stocks experienced significant movements, with companies like Golden Sun Health Technology Group Limited (NASDAQ:GSUN) and MMTec, Inc. (NASDAQ:MTC) seeing substantial gains. The article also highlights losers of the day, including Holdco Nuvo Group D.G Ltd (NASDAQ:NUVO) and The Real Good Food Company, Inc. (NASDAQ:RGF), which saw notable declines.

Portfolio Pulse from Avi Kapoor

May 07, 2024 | 6:35 pm

COIN

The article discusses a strategy for taking advantage of the pullback in cryptocurrency by focusing on 'picks and shovels' plays, particularly highlighting a bullish stance on Coinbase Global, Inc. (NASDAQ:COIN) despite its recent earnings beat not spiking the stock price, likely due to a pullback in Bitcoin. The author plans to place a bullish bet on COIN, aiming for a 20% upside by the next earnings release, and also mentions holding a bullish options trade on another unnamed company releasing earnings this week.

Portfolio Pulse from David Pinsen

May 07, 2024 | 6:33 pm

JNJ

Johnson & Johnson (NYSE:JNJ) shared data on its TARIS platform for bladder cancer, with Goldman Sachs noting a peak revenue potential of over $5 billion. The therapy, requiring no general anesthesia, targets high-risk bladder cancer patients, with a submission planned for early 2025. JNJ's stock rose 0.22% to $148.90.

Portfolio Pulse from Vandana Singh

May 07, 2024 | 6:31 pm